Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (October 2018)
19 slides from Bio-gene Technology's investor presentation, October 2018
Slide 1: Investor Presentation October 2018
(ASX:BGT) Investor Presentation October 2018
Slide 2: The Global Problem of Pest Control
The Global Problem of Pest Control The Ag-Chem industry is seeking new & safer Pest Environmental chemistry as global resistance Resistance Impact continues to worsen Pests are rapidly Public outrage at incumbent developing resistance to products’ toxic impact on bees current insecticides & other be
Slide 3: In recent years the problem has worsened
In recent years the problem has worsened Increasing number of resistant species New insecticides are increasingly elusive 700 160,000 Species Resistant Molecules Screened 586 insect species now >140,000 molecules must 600 resistant to at least one 140,000 be screened to discover a insecticide class
Slide 4: New compounds must demonstrate multiple qualities
New compounds must demonstrate multiple qualities Safe Novel Mode Efficacy Scalability Chemistry of Action Compound must New ‘soft chemistries‘ Compounds must Technology must be effective, are required, have a novel Mode be able to be either alone or which don’t of Action (MoA) produced at a in comb
Slide 5: Bio-Gene's technology addresses these needs
Bio-Gene’s technology addresses these needs Safe Novel Mode Efficacy Scalability Chemistry of Action Data shows Flavocide™ Trials show relatively Bio-Gene’s compounds CSIRO collaboration & Qcide™ are highly low toxicity to operate via a has refined effective for controlling bees & other novel Mode o
Slide 6: Bio-Gene has two unique compounds
Bio-Gene has two unique compounds Qcide™ Flavocide™ Natural Compound Nature Identical Compound Extract of an A chemical process is Australian eucalypt: used to produce a ‘Gypmie Messmate’ ‘synthetic copy’ of the compound that can be Qcide™ is well suited mass produced to applications in consumer pro
Slide 7: Well-defined pathway to commercialisation
Well-defined pathway to commercialisation Testing & Data Generation Well Create suite of trial data & IP relating to efficacy, toxicity, mode of action and manufacturing Progressed Introductory Commercial Discussions Globally Present Bio-Gene to major Ag-Chem, Government Agencies, NGO’s & Underway P
Slide 8: Bio-Gene has delivered on multiple milestones in 2018
Bio-Gene has delivered on multiple milestones in 2018 Significant Suite of Trial Data Toxicology Studies to Multiple Partnership for Proof of Concept Support Registration Discussions Efficacy Testing Expanded Knowledge Strengthened Improved Appointed Expert of Mode of Action Intellectual Manufacturi
Slide 9: Trial Data for Proof of Concept Efficacy Testing
Trial Data for Proof of Concept Efficacy Testing Objective Demonstrate effectiveness against pests that are resistant to other classes of chemistry Create suite of testing data across key verticals, to de-risk technology, & support discussions with major Ag-Chem businesses Results achieved in 2018 t
Slide 10: Toxicology Studies to Support Registration
Toxicology Studies to Support Registration Objective Demonstrate the safety of the technology & fulfil registration requirements Achieved in 2018 ✓ Continued formal toxicology & environmental safety studies with accredited third parties to perform necessary testing: • 28-day Oral & Dermal Tox Studie
Slide 11: Multiple Partnership Discussions
Multiple Partnership Discussions Objective Identify appropriate partners for product evaluation & development Achieved in 2018 ✓ Held multiple meetings in Australia, Europe, US & Asia, with Major Ag-Chem Producers, Government agencies & Not-for-Profit Organisations, covering all key verticals Contin
Slide 12: Expanded Knowledge of Mode of Action
Expanded Knowledge of Mode of Action Objective Clarify the specifics of the Mode of Action (“MoA”) to apply for a new class of chemistry via IRAC & support IP portfolio Achieved in 2018 ✓ • MoA confirmed via electrophysiological testing by world-class group • Supported by multiple efficacy test data
Slide 13: Strengthened Intellectual Property
Strengthened Intellectual Property Objective Generate data to support current & future patent filings & Intellectual Property Achieved in 2018 ✓ Two additional patent applications lodged Significant manufacturing Intellectual Property Next Steps Continue to identify opportunities to develop Intellec
Slide 14: Improved Manufacturing Capability
Improved Manufacturing Capability Objective Improve cost & yield of current manufacturing processes for Qcide™ & Flavocide™ Achieved in 2018 ✓ • Partnership with CSIRO has delivered substantial improvement in the cost of production of Flavocide™ with improved purity and yield • Partnership with Jame
Slide 15: Appointed Expert Advisors
Appointed Expert Advisors Objective Engage specialists in related fields to assess data & assist with next stage testing DOUG RATHBONE PROF. CATHERINE HILL NEIL ANDERSON Advisor to the BGT Board Purdue University Chemistry & BGT Scientific Advisory Manufacturing Consultant Board Member ✓ • >40 years
Slide 16: Q&A
Q&A *Click links to launch Articles 16
Slide 17: Financial Overview
Financial Overview Strong Cash Position $0.30 2 Volume (m) BGT has a well funded balance sheet $0.20 with ~$6.7m in cash (as at end FY18), providing a ~2 year runway 1 $0.10 Capital Structure & Financials Shares on Issue 128m $- 0 Nov-17 Feb-18 May-18 Aug-18 Share Price (Oct-18) $0.13 Volume Share P
Slide 18: Board & Management
Board & Management DON BRUMLEY RICHARD JAGGER PETER MAY Non-Executive Chairman CEO & Managing Director Executive Director, R & D • 25+ years as a senior partner & leader of • 20+ years working in agriculture globally • 20+ years experience in crop protection Ernst & Young – Oceania • Most recently e
Slide 19: Richard Jagger / Roger McPherson contacts
Richard Jagger Roger McPherson CEO CFO, Co. Sec. +61 3 9628 4178 +61 3 9628 4178 richardj@bio-gene.com.au rogerm@bio-gene.com.au
Bio-Gene Technology — Investor Presentation (October 2018) on 6ix